Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 17

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 17
---
#### Core Income Tax Expenses
Core Income Tax Expenses were JPY 132.8 billion (JPY -26.3 billion and -16.5% AER , -3.6% CER ). The decrease was primarily due to a reduction of tax expenses recognized in connection with the reassessment of the recoverability of Deferred Tax Assets partially offset by lower tax credits for the six-month period ended September 30, 2025.

#### Core

#### EPS
Core EPS was JPY 279 (JPY -31 and -10.0% AER, -10.8% CER).

<div align='center'>- 10 -</div>

Translation for reference purpose only

### (2) Consolidated Financial Position
|                   |     | Billion JPY 
 As of       | March 31, 2025 |     |     | September 30, 2025 |     | Change |       |
|:------------------|:----|:------------|---------------:|:----|:----|-------------------:|:----|:-------|------:|
| Total Assets      |     |             |       14,248.3 |     |     |           14,470.3 |     |        | 222.0 |
| Total Liabilities |     |             |        7,312.4 |     |     |            7,338.6 |     |        |  26.2 |
| Total Equity      |     |             |        6,936.0 |     |     |            7,131.7 |     |        | 195.7 |

#### Assets
Total Assets as of September 30, 2025 were JPY 14,470.3 billion ( JPY +222.0 billion). Cash and cash equivalents increased (JPY +296.4 billion). Goodwill increased ( JPY +107.3 billion ) mainly due to the effect of foreign currency translation. Inventories increased ( JPY +82.1 billion ) primarily driven by higher work-in-process and finished goods related to PDT products and ENTYVIO, as well as the effect of foreign currency translation. These increases were partially offset by the decrease of Intangible Assets ( JPY -332.3 billion) m ainly due to amortization .

#### Liabilities
Total Liabilities as of September 30, 2025 were JPY 7,338.6 billion ( JPY +26.2 billion